Lakefront Biotherapeutics Sells Cell Therapy Pipeline for Up to $230M
Lakefront Biotherapeutics NV (EURONEXT:LKFT) has agreed to sell its preclinical CAR-T cell therapy pipeline to Armed Cell Therapeutics. Under the deal terms, Lakefront receives an initial upfront payment of 8 million euros, along with potential milestone payments that could reach up to $230 million. Lakefront is also eligible to collect low-single-digit royalties if any of the assets successfully reach the market.
The sale follows Lakefront's decision to wind down its cell therapy activities. By divesting these early-stage assets, the biopharmaceutical company completes its strategic exit from cell therapy, freeing up resources and reducing cash burn and operational complexity. The transition allows the business to narrow its strategic focus onto its remaining T-cell engager pipeline.
Investors will be watching for future updates on Lakefront's core T-cell engager programs, including potential partnership deals and clinical progress. Additional financial upside remains tied to the timeline and achievement of the milestone triggers under the agreement with Armed Cell Therapeutics. Shares of Lakefront Biotherapeutics were trading down 0.76% at 26.04 EUR following the announcement.
Key points
- Lakefront Biotherapeutics NV is selling its preclinical CAR-T pipeline to Armed Cell Therapeutics for an upfront payment of 8 million euros.
- The deal includes contingent milestone payments of up to $230 million plus low-single-digit royalties on future product sales.
- The divestment marks the completion of Lakefront's strategic exit from cell therapy operations.
- The company is redirecting its operational focus toward its T-cell engager development portfolio.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
How much is Lakefront Biotherapeutics receiving from the cell therapy sale?
Lakefront Biotherapeutics receives an upfront payment of 8 million euros, up to $230 million in potential milestone payments, and low-single-digit royalties on future sales.
Why did Lakefront Biotherapeutics sell its preclinical CAR-T pipeline?
Lakefront sold the pipeline to complete its wind-down of cell therapy activities and streamline its strategic focus on T-cell engager programs.
Who purchased Lakefront Biotherapeutics' CAR-T programs?
Armed Cell Therapeutics acquired the preclinical cell therapy assets.